Morgan Stanley raised the firm’s price target on BrightSpring Health (BTSG) to $48 from $40 and keeps an Overweight rating on the shares. The firm update its model post-Q4 earnings to reflect the Amedisys/LHC acquisition in the Provider Services segment.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $50 from $45 at Mizuho
- BrightSpring Health 20M share Spot Secondary priced at $41.15
- BrightSpring Health 20M share Spot Secondary; price range $41.15-$41.58
- BrightSpring Health announces offering of 20M shares of common stock for holders
- BrightSpring Health price target raised to $53 from $48 at UBS